Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pacira BioSciences stock

Own Pacira BioSciences stock in just a few minutes.

Fact checked

Pacira BioSciences, Inc is a drug manufacturers-specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira BioSciences employs 606 staff and has a trailing 12-month revenue of around USD$421.1 million.

How to buy shares in Pacira BioSciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pacira BioSciences. Find the stock by name or ticker symbol: PCRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pacira BioSciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pacira BioSciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pacira BioSciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pacira BioSciences share price

Use our graph to track the performance of PCRX stocks over time.

Pacira BioSciences shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$27.46 - USD$79.98
50-day moving average USD$71.4709
200-day moving average USD$62.2945
Wall St. target priceUSD$74.15
PE ratio 25.5203
Dividend yield N/A (0%)
Earnings per share (TTM) USD$2.931

Buy Pacira BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pacira BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Pacira BioSciences under- or over-valued?

Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pacira BioSciences's P/E ratio

Pacira BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Pacira BioSciences shares trade at around 26x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Pacira BioSciences's EBITDA

Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$54.9 million.

The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.

Pacira BioSciences financials

Revenue TTM USD$421.1 million
Operating margin TTM 9.65%
Gross profit TTM USD$242.2 million
Return on assets TTM 2.51%
Return on equity TTM 27.1%
Profit margin 29.95%
Book value $13.499
Market capitalisation USD$3.2 billion

TTM: trailing 12 months

Shorting Pacira BioSciences shares

There are currently 6.2 million Pacira BioSciences shares held short by investors – that's known as Pacira BioSciences's "short interest". This figure is 5.3% down from 6.6 million last month.

There are a few different ways that this level of interest in shorting Pacira BioSciences shares can be evaluated.

Pacira BioSciences's "short interest ratio" (SIR)

Pacira BioSciences's "short interest ratio" (SIR) is the quantity of Pacira BioSciences shares currently shorted divided by the average quantity of Pacira BioSciences shares traded daily (recently around 589652.27272727). Pacira BioSciences's SIR currently stands at 10.56. In other words for every 100,000 Pacira BioSciences shares traded daily on the market, roughly 10560 shares are currently held short.

However Pacira BioSciences's short interest can also be evaluated against the total number of Pacira BioSciences shares, or, against the total number of tradable Pacira BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacira BioSciences's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Pacira BioSciences shares in existence, roughly 140 shares are currently held short) or 0.2014% of the tradable shares (for every 100,000 tradable Pacira BioSciences shares, roughly 201 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pacira BioSciences.

Find out more about how you can short Pacira BioSciences stock.

Pacira BioSciences share dividends

We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.

Pacira BioSciences share price volatility

Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $27.46 up to $79.98. A popular way to gauge a stock's volatility is its "beta".

PCRX.US volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 1.1345. This would suggest that Pacira BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pacira BioSciences overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site